CCND2
CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
Overview
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase.
CIViC holds 7 clinical evidence items and 0 assertions across 3 variants, naming Palbociclib. Open Targets scores its association with cancer at 0.76 (direct and indirect evidence; datatypes literature 0.99, affected pathway 0.69, genetic association 0.60, somatic mutation 0.85). IntOGen calls it a driver in 3 cohorts (1 activating, 2 loss-of-function), covering Acute Myeloid Leukaemia, Chronic Lymphocytic Leukaemia/Small Lymphocytic Lymphoma.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
- 1 · What it is
CCND2 (G1/S-specific cyclin-D2) is a gene whose normal job is to hold cell growth in check. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Colorectal cancer, Skin cancer and 4 more.
- 2 · What goes wrong in cancer
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition.
- 3 · How drugs use it
No product in this corpus aims at CCND2 yet. Because the protein is lost rather than overactive, drugs either restore its function or exploit the weakness its loss leaves (synthetic lethality).
External identifiers
Sources: HGNC HGNC:1583 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P30279 (protein name, function text, keywords and locations (REST API)); CIViC gene CCND2 (7 evidence items, 0 assertions, 3 variants; diseases: Stomach Cancer, Lung Squamous Cell Carcinoma, Cancer (GraphQL API, CC0)); Open Targets ENSG00000118971 (association with cancer (MONDO_0004992) 0.76; per-cancer scores at or above 0.5: colorectal cancer 0.59, melanoma 0.56, skin cancer 0.55 (GraphQL API, CC0)); IntOGen CCND2 (driver in 3 cohorts (Act 1, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Regulatory component of the cyclin D2-CDK4 (DC) complex that phosphorylates and inhibits members of the retinoblastoma (RB) protein family including RB1 and regulates the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complex and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Location: Nucleus; Cytoplasm; Nucleus membrane (UniProt). Locus 12p13.32 (HGNC).
- Gastric & gastro-oesophageal junction cancer: CIViC evidence names this disease
- Colorectal cancer: Open Targets association 0.59 with colorectal cancer (MONDO_0005575)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Non-small-cell lung cancer: CIViC evidence names this disease
- Chronic lymphocytic leukaemia: IntOGen driver in 2 cohorts (CLLSLL)
- Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 1 cohort; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 7 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
Latest papers
topQuery for this target: (TITLE:"CCND2" OR ABSTRACT:"CCND2" OR TITLE:"cyclin D2" OR ABSTRACT:"cyclin D2" OR TITLE:"G1/S-specific cyclin-D2" OR ABSTRACT:"G1/S-specific cyclin-D2") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CCND2, not a curated reading list.